Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

610 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).
Arnold SM, Chansky K, Leggas M, Thompson MA, Villano JL, Hamm J, Sanborn RE, Weiss GJ, Chatta G, Baggstrom MQ. Arnold SM, et al. Among authors: hamm j. Invest New Drugs. 2017 Oct;35(5):608-615. doi: 10.1007/s10637-017-0441-4. Epub 2017 Feb 16. Invest New Drugs. 2017. PMID: 28204981 Free PMC article. Clinical Trial.
Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy.
Arnold SM, Chansky K, Baggstrom MQ, Thompson MA, Sanborn RE, Villano JL, Waqar SN, Hamm J, Leggas M, Willis M, Rosales J, Crowley JJ. Arnold SM, et al. Among authors: hamm j. Clin Lung Cancer. 2020 Jul;21(4):357-364.e7. doi: 10.1016/j.cllc.2020.01.006. Epub 2020 Jan 27. Clin Lung Cancer. 2020. PMID: 32173247 Clinical Trial.
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, Ramanathan RK, Borad MJ, Tibes R, Cohn A, Hinshaw I, Jotte R, Rosen LS, Hoch U, Eldon MA, Medve R, Schroeder K, White E, Von Hoff DD. Jameson GS, et al. Among authors: hamm jt. Clin Cancer Res. 2013 Jan 1;19(1):268-78. doi: 10.1158/1078-0432.CCR-12-1201. Epub 2012 Nov 7. Clin Cancer Res. 2013. PMID: 23136196 Free PMC article. Clinical Trial.
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, Huang J, Algan O, Deb N, Portelance L, Villano JL, Hamm JT, Oh KS, Ali AN, Kim MM, Lindhorst SM, Mehta MP. Tsien CI, et al. Among authors: hamm jt. J Clin Oncol. 2023 Feb 20;41(6):1285-1295. doi: 10.1200/JCO.22.00164. Epub 2022 Oct 19. J Clin Oncol. 2023. PMID: 36260832 Free PMC article. Clinical Trial.
A phase II trial of chlorambucil in non-small cell lung cancer.
Gentile PS, Woodcock TM, Blumenreich MS, Epremian BE, Seeger J, Sheth SP, Hamm JT, Sherrill EJ, Allegra JC. Gentile PS, et al. Among authors: hamm jt. Am J Clin Oncol. 1987 Dec;10(6):515-6. doi: 10.1097/00000421-198712000-00011. Am J Clin Oncol. 1987. PMID: 2825510
Inefficacy of low-dose continuous oral etoposide in non-small cell lung cancer.
Blumenreich MS, Sheth SP, Miller CL, Farnsley ES, Kellihan MJ, Joseph UG, Hamm JT, Seeger J, Robinson LH, Hagan PC, et al. Blumenreich MS, et al. Among authors: hamm jt. Am J Clin Oncol. 1994 Apr;17(2):163-5. doi: 10.1097/00000421-199404000-00015. Am J Clin Oncol. 1994. PMID: 8141109 Clinical Trial.
610 results